The federal government has been working with provincial and territorial colleagues, as well as networks of academic centres, in developing what's been called a real world drug safety and effectiveness network, which will be used to collect data about real world impacts, tapping into administrative databases and the like. There has been a business case developed on that. That's under continuing discussion between governments, with hopes to advance that. That would also form another source of data that can be used and tapped into by the regulator in terms of looking at real world impacts of pharmaceuticals.
